The ability to track neuroinflammation throughout Alzheimer's disease progression could transform how clinicians monitor treatment responses and identify optimal intervention windows. This capability becomes increasingly critical as therapeutic targets shift toward earlier disease stages where brain damage remains potentially reversible.
Analysis of cerebrospinal fluid from 834 participants revealed 109 dysregulated microglia-related proteins that change systematically as Alzheimer's advances from preclinical stages through dementia. In early disease phases, protein patterns reflected innate immune activation and cellular recruitment processes. However, as the condition progressed to clinical dementia, the immune response shifted toward adaptive immunity pathways and macrophage-mediated responses, suggesting fundamental changes in how brain immune cells respond to accumulating pathology.
The research team developed an 18-protein panel capable of distinguishing between preclinical and dementia stages, offering a potential clinical tool for disease staging. Importantly, when researchers compared these real-world protein profiles with laboratory-derived gene expression signatures from microglia, they found that established transcriptomic markers spanned both disease stages rather than being specific to particular phases.
This work addresses a significant gap in Alzheimer's biomarker development, where most current markers focus on amyloid and tau pathology rather than the inflammatory processes that drive neuronal damage. The stage-specific immune signatures could enable more precise patient stratification in clinical trials and help explain why anti-inflammatory interventions show variable efficacy depending on disease timing. However, the observational design cannot establish whether these protein changes drive disease progression or simply reflect it, and validation across diverse populations remains essential.